Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc

Bullboard Posts

Comment by JLGeminion Dec 30, 2010 7:52am

342 Views

Post# 17905259

RE: RE: RE: RE: RE: RE: RE: Musings. Hogwash

Thanks Cardu. I made a typo due to rushing. I would say that the sentence was more cryptic than incoherent or incoherant as you prefer. For you, I missed typing the “r” in "you" to make "your" whole. I was crediting the investment club for spiking Oncolytics’ stock price from its 52 week high in 2009 and using this Board to influence ONC’s close of $2.75 on Dec 31, 2009.

Bullboard Posts

Cameco raises uranium output as Q3 results surge